DMRA

NASDAQ 已收盘

Damora Therapeutics

24.30 USD
▲+1.32+5.74%
盘后 25.00 +2.88%
2026-11-19
市值
$1.44B
市盈率
—
EPS
-6.64
股息率
—
52 周区间
15.76 – 38.33
成交量
548.78K
Beta
1.51
目标价
46.78
52W 低 15.7652W 高 38.33
价格走势

公司简介

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen...